Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer

Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer

Item
http://www.wikidata.org/entity/Q28259929
Therapeutic targeting of cancers with loss of PTEN function.Preclinical pharmacological evaluation of a novel multiple kinase inhibitor, ON123300, in brain tumor modelsRecent treatment advances and novel therapies in pancreas cancer: a review.Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignanciesA phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancerEfficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells.The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.The ubiquitin proteasome system - implications for cell cycle control and the targeted treatment of cancer.Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer.Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells.Hydrothiolation of benzyl mercaptan to arylacetylene: application to the synthesis of (E) and (Z)-isomers of ON 01910·Na (Rigosertib®), a phase III clinical stage anti-cancer agent.Determination of intestinal permeability of rigosertib (ON 01910.Na, Estybon): correlation with systemic exposure.Engineered Zn(II)-Dipicolylamine-Gold Nanorod Provides Effective Prostate Cancer Treatment by Combining siRNA Delivery and Photothermal Therapy.Genome wide expression analysis of radiation-induced DNA damage responses in isogenic HCT116 p53+/+ and HCT116 p53-/- colorectal carcinoma cell lines.
P2860

Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer

Item
http://www.wikidata.org/entity/Q28259929
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Phase I study of Rigosertib, a ...... d tumors and pancreatic cancer
@ast
Phase I study of Rigosertib, a ...... d tumors and pancreatic cancer
@en
Phase I study of Rigosertib, a ...... d tumors and pancreatic cancer
@nl
type
label
Phase I study of Rigosertib, a ...... d tumors and pancreatic cancer
@ast
Phase I study of Rigosertib, a ...... d tumors and pancreatic cancer
@en
Phase I study of Rigosertib, a ...... d tumors and pancreatic cancer
@nl
prefLabel
Phase I study of Rigosertib, a ...... d tumors and pancreatic cancer
@ast
Phase I study of Rigosertib, a ...... d tumors and pancreatic cancer
@en
Phase I study of Rigosertib, a ...... d tumors and pancreatic cancer
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P698
P356
P1433
P1476
Phase I study of Rigosertib, a ...... d tumors and pancreatic cancer
@en
P2093
P304
P31
P356
10.1158/1078-0432.CCR-11-2813
P407
P433
P478
P577
P698